Consistent control of mineral and bone disorder in incident hemodialysis patients
about
A New Data Analysis System to Quantify Associations between Biochemical Parameters of Chronic Kidney Disease-Mineral Bone DiseaseAnalysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients.The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?Pharmacology of the phosphate binder, lanthanum carbonateA comparison of the long-term effects of lanthanum carbonate and calcium carbonate on the course of chronic renal failure in rats with adriamycin-induced nephropathyParathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort studyUtilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease.The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysisLanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.Refining the definition of clinically important mineral and bone disorder in hemodialysis patientsDecreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.Effects of phosphate binders in moderate CKDFacility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysisSerum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction.Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis PatientsPrevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India.Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.Cinacalcet: will it play a role in reducing cardiovascular events?Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.Dietary educational interventions for management of hyperphosphatemia in hemodialysis patients: a systematic review and meta-analysis.Chronic Kidney Disease-Mineral and Bone Disorder in Asia.Simplified phosphorus kinetic modeling: predicting changes in predialysis serum phosphorus concentration after altering the hemodialysis prescription.Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.[Management of secondary hyperparathyroidism-current impact of parathyroidectomy].AN OVERVIEW OF NURSES' MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM: HOW IS EUROPE DOING?Relationship between mild-to-moderate chronic kidney disease and decreased bone mineral density in Chinese adult population.Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'?Effect of stage-based education provided by dedicated dietitians on hyperphosphataemic haemodialysis patients: results from the Nutrition Education for Management of Osteodystrophy randomised controlled trial.Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
P2860
Q28552810-C07DFF64-F97F-4E52-A9D1-E627AA4BF415Q33890218-FD6F14FA-7D38-42DB-9B98-9FAC7398DA90Q34293730-D69E614F-C720-443F-A5AA-1B04E2E5F13AQ34366087-490C6048-4393-4752-BABB-DA315DB2C9D5Q34854318-BE8A91A1-D7C3-4A93-A5B3-3EF40EF59BD9Q35171681-76A9A741-991B-420C-B023-B2ED406421E7Q35247578-255DF76F-6E71-4540-84A1-24DD7060D399Q35452299-3E1013E9-DD44-431A-A56F-C2454791293CQ35635182-ED9D5BC2-0CF4-4EF6-9D75-33F58AD1328DQ35804097-1706D92A-FC3C-459C-964F-A81499D4A1A9Q35811676-CA5936D0-2684-4306-AF17-36B57DB9FDA5Q35886018-8E8517B5-0DDF-45F5-8AAB-FF6030605C40Q35983513-1AC0DC08-DB29-41F4-BB0C-69F58CD3B439Q36109201-376B3314-A277-484D-A8CF-6B63C063C62CQ36183258-E5777E9D-F777-4ABE-B903-F1AD88DDEC80Q36880126-8AC3EE71-FA19-4BDF-8579-E389C78182B4Q36965339-C50337E3-49FD-44E4-8D3D-0FF732DA6A80Q37015581-9484AFF2-FEF2-471E-B2FB-421976E2142AQ37275615-8DA514E2-3D08-46BB-870F-A6DA6BA8B32AQ37324775-7A55DC6E-2937-4C5B-BB16-E14817C28A18Q37359078-CC6CEF53-A3F0-4050-91FF-203C1D47D885Q37916534-13BC1926-AE2A-44F1-8ADA-F6084FF770A1Q37993874-9A5B61C0-1D47-4F0E-AFA6-0F6DCCF31500Q38141236-22F80DEE-4327-4AAD-977E-E0CBAA92C479Q38219626-14FC8A9F-AA2A-49FF-8543-F02B11876941Q38635767-C4870387-CB74-457B-981D-21360F52D6E7Q39244833-F640C867-F33B-427F-814C-B91471BF419AQ39946556-C8883EB1-E22F-448A-918D-74D93210EC4CQ40889096-78FFA2CE-2F81-42E5-877E-BF267C6F033FQ41032434-BA85BC61-A7F7-4A55-A4FF-D47ACB0FF270Q41491440-B9978B16-85C8-4C01-8C94-797244BB4B64Q43405909-7E22ECFB-DA0D-454C-8DF5-C66E8B8F41DCQ43427754-B4EB637A-29BD-4F41-8686-A3D9D7A58E99Q43826461-E122888D-C474-4577-AAD3-D6022BFE7BDFQ44186583-2CE6CB2D-1AC4-4E25-8C7F-B40FD1DA3EC8Q45160013-3EC42124-62AB-49B1-B34D-1203EDAC1A56Q49166621-F41EFF99-F1C1-4071-A432-1EA4AA34CD58Q50022061-D70D7F4E-6B84-419B-87B8-141DA6F09BEBQ50786312-1816D0F0-6A4F-465E-8F61-26BBCBCFE082Q51249822-45D930E2-EA64-4C14-A4D7-691AB498C379
P2860
Consistent control of mineral and bone disorder in incident hemodialysis patients
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Consistent control of mineral and bone disorder in incident hemodialysis patients
@en
type
label
Consistent control of mineral and bone disorder in incident hemodialysis patients
@en
prefLabel
Consistent control of mineral and bone disorder in incident hemodialysis patients
@en
P2093
P2860
P356
P1476
Consistent control of mineral and bone disorder in incident hemodialysis patients
@en
P2093
Karen Smirnakis
Mark D Danese
Vasily Belozeroff
P2860
P304
P356
10.2215/CJN.01060308
P577
2008-07-02T00:00:00Z